M/s. Casa DE Representaciones Pharmaceutical Import Profile — Venezuela (DGFT 2022–2026)

Name: M/s. Casa DE Representaciones Pharmaceutical Import Records from India — 3 Products, $700.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Casa DE Representaciones — Pharmaceutical Importer Profile (2026) | 3 Products, $700.0K Trade | TransData Nexus

M/s. Casa DE Representaciones

Pharmaceutical Importer · Venezuela · Antifungals Focus · $700.0K Total Trade · DGFT Verified

M/s. Casa DE Representaciones is a pharmaceutical importer based in Venezuela with a total trade value of $700.0K across 3 products in 2 therapeutic categories. Based on 14 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Casa DE Representaciones sources from 1 verified Indian supplier, with Galentic Pharma India Private Limited accounting for 100.0% of imports.

M/s. Casa DE Representaciones — Import Portfolio & Supplier Network

M/s. Casa DE Representaciones import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Casa DE Representaciones?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Galentic Pharma India Private Limited	$1.6M	47	100.0%

M/s. Casa DE Representaciones sources from 1 verified Indian supplier across 29 distinct formulations. The sourcing is highly concentrated — Galentic Pharma India Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Harmless medicines ketoconazol shampoo 2%, 100 ML (ketoconazole shampoo BP 2%)	$200.0K	4
Harmless medicines terbinafine hydrochloride cream, 15g (terbinafine hydrochloride cream)	$195.2K	4
Harmless medicines fixadol, 20g (diclofenac gel BP)	$174.7K	4
Harmless medicines nystatin cream 100000 IU, 30g (nystatin cream USP 100000iu)	$142.1K	4
Harmless medicines trialivio crema topica 30GM (betamethasone dipropionate with gentamicin sulphate & clotrimazole	$100.0K	2
Harmless medicines betametasona dipropionato 0.05% crema topica,15g (betamethasone dipropionate cream USP 0.05%)	$68.0K	4
Harmless medicines candigen crema	$64.3K	2
Harmless medicines pyloocain ointment	$50.0K	1
Harmless medicines clotrimazole 2%	$50.0K	1
Harmless medicines bacitracina zinc 500 ui unguento topico (bacitracin zinc ointment USP)	$50.0K	1
Harmless medicines trialivio crema topica 30g( betamethasone dipropionate withgentamicin sulfate & clotrimazole	$50.0K	1
Harmless medicines venaproct ,30g (betamethasone valerate BP 0.05% + phenylephrine hydrochloride BP 0.1% + lidocaine	$50.0K	1
Harmless medicines calafin calamina 100ML (calamine lotion 15% BP)	$47.8K	2
Harmless medicines clotrimazole 1%	$44.2K	1
Harmless medicines ketoconazol shampoo 2%, 100ML (ketoconazole shampoo BP 2%)	$42.8K	1

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Clotrimazole	Antifungals	$300.0K	6	0.3%	11
2	Ketoconazole	Antifungals	$250.0K	5	0.6%	17
3	Gentamicin	Antibiotics	$150.0K	3	0.3%	6

M/s. Casa DE Representaciones imports 3 pharmaceutical products across 2 categories into Venezuela totaling $700.0K.

M/s. Casa DE Representaciones — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Casa De Representaciones is a pharmaceutical importer based in Venezuela, specializing in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in the Venezuelan pharmaceutical distribution network, ensuring the availability of essential medications to meet the country's healthcare needs. While specific details about its parent company and exact headquarters are not publicly disclosed, M/s. Casa De Representaciones is recognized for its significant contributions to the pharmaceutical sector in Venezuela.

2Distribution Network

The company's distribution network encompasses various regions within Venezuela, facilitating the widespread availability of imported pharmaceutical products. While specific warehouse locations and logistics capabilities are not publicly detailed, M/s. Casa De Representaciones is known to collaborate with international suppliers to ensure a steady supply of medications. The company's operations are primarily focused within Venezuela, with no publicly available information indicating expansion beyond its national borders.

3Industry Role

M/s. Casa De Representaciones functions as a primary wholesaler in Venezuela's pharmaceutical supply chain. By importing and distributing finished pharmaceutical formulations, the company bridges the gap between international manufacturers and the local market, ensuring that essential medications are accessible to healthcare providers and patients across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Casa DE Representaciones

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

The company's sourcing strategy exhibits a high degree of concentration, with a total import value of $700,000 USD from India over 14 shipments, all sourced from a single supplier, GALENTIC PHARMA INDIA PRIVATE LIMITED. This single-source dependency may pose risks related to supply chain disruptions, currency fluctuations, and geopolitical factors affecting trade relations. However, the consistent volume of imports suggests a stable and reliable relationship between M/s. Casa De Representaciones and GALENTIC PHARMA INDIA PRIVATE LIMITED, indicating a strategic choice to maintain a focused and efficient supply chain.

2Supply Chain Resilience

The resilience of M/s. Casa De Representaciones's supply chain is closely tied to its exclusive partnership with GALENTIC PHARMA INDIA PRIVATE LIMITED. The lack of backup suppliers and limited formulation diversity may expose the company to risks in the event of supply disruptions. Additionally, the shipping routes and regulatory compliance of the supplier are critical factors influencing the supply chain's stability. While specific details about shipping routes and regulatory compliance are not publicly available, the company's reliance on a single supplier underscores the importance of maintaining a robust and compliant supply chain.

Strategic Implications

Importing Pharmaceuticals into Venezuela — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Venezuela

1Regulatory Authority & Framework

In Venezuela, the Ministry of Popular Power for Health (MPPS) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The MPPS is responsible for evaluating and approving import licenses for medications, ensuring that imported drugs meet the country's health and safety standards. The regulatory framework governing pharmaceutical imports includes the Organic Law on Narcotic and Psychotropic Substances, which imposes restrictions on the importation of certain substances to protect public health. Importers must adhere to these regulations to ensure compliance and maintain the integrity of the supply chain.

2Import Licensing & GMP

Importers of pharmaceutical products in Venezuela are required to obtain licenses from the MPPS. This process involves submitting detailed documentation, including product specifications and certificates of origin, to demonstrate compliance with Venezuelan health regulations. The MPPS evaluates these submissions to ensure that imported medications are safe and effective for public use. Additionally, the MPPS recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the World Health Organization (WHO) and the European Union (EU), as part of the import approval process. Importers must ensure that their suppliers hold valid GMP certifications to facilitate the importation of pharmaceutical products into Venezuela.

M/s. Casa DE Representaciones — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

M/s. Casa De Representaciones's focus on importing antifungal and antibiotic medications aligns with the prevalent healthcare needs in Venezuela. The high import value of clotrimazole and ketoconazole indicates a significant demand for antifungal treatments, while the inclusion of gentamicin suggests a need for antibiotic therapies. This strategic product selection is driven by the therapeutic requirements of the Venezuelan population, addressing common infections and contributing to public health management.

2Sourcing Profile

The company's sourcing strategy is centered on generic drug formulations, primarily sourced from India. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost-effectiveness. By focusing on generic formulations, M/s. Casa De Representaciones can offer affordable treatment options to the Venezuelan market, ensuring accessibility to essential medications.

3Market Positioning

Based on its product mix, M/s. Casa De Representaciones serves the wholesale distribution segment of the Venezuelan pharmaceutical market. By importing and distributing essential medications, the company ensures that healthcare providers have access to necessary treatments, thereby supporting the overall healthcare infrastructure in Venezuela.

Seller's Guide — How to Become a Supplier to M/s. Casa DE Representaciones

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with M/s. Casa De Representaciones. The company's concentrated sourcing pattern indicates a potential openness to diversifying its supplier base, which could enhance supply chain resilience and mitigate risks associated with single-source dependency. Indian exporters can explore this opportunity by ensuring compliance with Venezuelan regulatory standards and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters seeking to supply M/s. Casa De Representaciones and the Venezuelan market must obtain GMP certifications recognized by the MPPS, such as those from the WHO or EU. Additionally, they must ensure that their products meet Venezuelan quality and labeling standards, including batch testing, stability requirements, and Spanish-language labeling. Adhering to these requirements is crucial for successful market entry and sustained business relationships.

3How to Approach

Frequently Asked Questions — M/s. Casa DE Representaciones

What products does M/s. Casa DE Representaciones import from India?

M/s. Casa DE Representaciones imports 3 pharmaceutical products across 2 categories. Top imports: Clotrimazole ($300.0K), Ketoconazole ($250.0K), Gentamicin ($150.0K).

Who supplies pharmaceuticals to M/s. Casa DE Representaciones from India?

M/s. Casa DE Representaciones sources from 1 verified Indian suppliers. The primary supplier is Galentic Pharma India Private Limited (100.0% of imports, $1.6M).

What is M/s. Casa DE Representaciones's total pharmaceutical import value?

M/s. Casa DE Representaciones's total pharmaceutical import value from India is $700.0K, based on 14 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Casa DE Representaciones focus on?

M/s. Casa DE Representaciones imports across 2 categories. The largest: Antifungals (78.6%), Antibiotics (21.4%).

Get Full M/s. Casa DE Representaciones Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.